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Pivotal role of protein tyrosine phosphatase 1B
(PTP1B) in the macrophage response to
pro-inflammatory and anti-inflammatory challenge
PG Trave´s1,5, V Pardo1,2,5, M Pimentel-Santillana1,5, A´ Gonza´lez-Rodrı´guez1,2, M Mojena1, D Rico3, Y Montenegro1, C Cale´s1,
P Martı´n-Sanz1,4, AM Valverde*,1,2 and L Bosca´*,1,4
Inhibition of protein tyrosine phosphatase 1B (PTP1B) has been suggested as an attractive target to improve insulin sensitivity in
different cell types. In the present work, we have investigated the effect of PTP1B deficiency on the response of human and
murine macrophages. Using in vitro and in vivo approaches in mice and silencing PTP1B in human macrophages with specific
siRNAs, we have demonstrated that PTP1B deficiency increases the effects of pro-inflammatory stimuli in both human and
rodent macrophages at the time that decreases the response to alternative stimulation. Moreover, the absence of PTP1B induces
a loss of viability in resting macrophages and mainly after activation through the classic pathway. Analysis of early gene
expression in macrophages treated with pro-inflammatory stimuli confirmed this exacerbated inflammatory response in PTP1B-
deficient macrophages. Microarray analysis in samples from wild-type and PTP1B-deficient macrophages obtained after 24 h of
pro-inflammatory stimulation showed an activation of the p53 pathway, including the excision base repair pathway and the
insulin signaling pathway in the absence of PTP1B. In animal models of lipopolysaccharide (LPS) and D-galactosamine challenge
as a way to reveal in vivo inflammatory responses, animals lacking PTP1B exhibited a higher rate of death. Moreover, these
animals showed an enhanced response to irradiation, in agreement with the data obtained in the microarray analysis.
In summary, these results indicate that, although inhibition of PTP1B has potential benefits for the treatment of diabetes, it
accentuates pro-inflammatory responses compromising at least macrophage viability.
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Protein tyrosine phosphatase 1B (PTP1B) is a ubiquitously
expressed phosphatase that has emerged as a relevant
modulator of signaling pathways initiated by the activation of
the tyrosine kinase receptor superfamily.1 Clinically relevant,
PTP1B is a critical node of insulin signaling due to its ability to
dephosphorylate and inactivate the insulin receptor, thereby
switching off insulin signaling.2,3 Indeed, PTP1B-deficient
mice are a unique model of insulin hypersensitivity due to
enhanced insulin action.4–6 These mice are protected against
diet4,6 and age-induced obesity and insulin resistance linked
to a low grade of chronic inflammation in white adipose
tissue.7,8 PTP1B is also involved in the control of immune cell
signaling,9,10 controlling cytokine signaling pathways by
dephosphorylation of janus kinase 2 (JAK2), non-receptor
tyrosine-protein kinase 2 (TYK2) and signal transducer and
activator of transcription 5 (STAT5).11,12 Moreover, it has
been reported that interleukin-4 (IL-4) induced PTP1B mRNA
in a phosphatidylinositol 3-kinase (PI3K)-dependent manner
and enhanced PTP1B protein stability to suppress IL-4-
induced STAT6 signaling.13
PTP1B-deficient mice exhibited an increase in monocyte/
macrophages in the spleen and the bone marrow.14 This was
due to a decreased threshold of response to macrophage
colony-stimulating factor (M-CSF) by enhancing tyrosine
phosphorylation of the activation loop of its receptor
(M-CSF1R). In addition to lineage specification, PTP1B
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modulates activation of monocytes/macrophages. In fact, in
the absence of PTP1B tissue macrophages display an
activated phenotype assessed by the increased expression
of CD80 that has a role in the maintenance of inflammation.
However, this effect might require developmental adaptations
in macrophages since short-term treatment of mice with the
PTP1B inhibitor suramin protects against apoptotic liver
damage induced by CD95 and against endotoxic shock
mediated by tumor necrosis factor-a (TNF-a).15
In this work, we have characterized the effect of PTP1B
deficiency on the early signaling in response to pro-
inflammatory challenge in murine and human macrophages.
Our data show that in the absence of PTP1B both classic and
innate responses (M1 polarization) are overactivated at the
time that alternative polarization (M2) is reduced.16,17 Studies
using in vivo models provide support to these enhanced pro-
inflammatory responses. However, these data also suggest
that the broad use of PTP1B inhibitors, although with potential
benefits over the insulin signaling pathway, might exert
undesirable effects on response to stressors of the immune
system including the fine tuning of the pro-inflammatory and
pro-resolution balance.
Results
PTP1B deficiency results in enhanced M1 responses
and attenuated activation by M2 stimuli. Peritoneal
macrophages from wild-type (WT) and PTP1B-deficient mice
were activated with lipopolysaccharide (LPS) and polyriboi-
nosinic:polyribocytidylic acid (polyI:C) (M1 stimuli) and the
expression of genes characteristic of the innate immune
response was determined. PTP1B deficiency results in an
enhancement in the levels of these M1 representative genes
(Figure 1a). In the same way, challenge with combinations of
IL-4 and IL-13 (M2 cytokines) decreased heme oxygenase 1
(HO-1) and arginase-1 (Arg-1) expression reflecting attenua-
tion of M2 responses in PTP1B knockout (KO) macrophages
(Figure 1b). Interestingly, PTP1B levels were upregulated
upon M1 or M2 challenge (Figure 1c). The accumulation of
nitric oxide (NO), prostaglandin E2 (PGE2) and TNF-a in the
culture medium (Figure 1d), and the time course of the rise in
the mRNA levels of IL-6 and nitric oxide synthase-2 (NOS-2)
(Figure 1e) were potentiated in PTP1B KO macrophages
upon M1 activation. Moreover, a significant loss of viability
was observed in PTP1B-deficient cells after 48–72 h of
culture (Figure 1f).
Early pro-inflammatory signaling in PTP1B-deficient
peritoneal macrophages. To evaluate the impact of
PTP1B deficiency on the early response of macrophages
to LPS, the nuclear factor-kB (NF-kB) pathway was
analyzed. The degradation of IkBa was more efficient in
PTP1B KO versus the WT counterparts, at the time that the
late recovery by resynthesis was impaired (Figure 2a). This
was also confirmed when the kinetics of the IkBa mRNA
levels was determined (Figure 2b). Similar results were
observed for IkBb. Regarding the interferon (IFN) regulated
factor 3 (IRF-3) pathway, our data show a lesser upregulation
in PTP1B KO macrophages, confirming previous work.18
Finally, the absence of PTP1B resulted in a higher
translocation of p65 from the cytosol to the nucleus
(Figure 2c).
The phosphorylation state of protein kinase B (AKT) and the
mitogen-activated protein kinases (MAPKs), two well-known
targets activated after LPS challenge, was investigated. As
Figure 3a shows, AKT phosphorylation was sustained in cells
lacking PTP1B. The same response was evidenced in the
MAPKs extracellular signal-regulated kinase (ERK), p38 and
c-Jun N-terminal kinase (JNK). Since PI3K has a role in the
attenuation of the response to LPS in macrophages,19,20 cells
lacking PTP1B were incubated with the PI3K inhibitor
LY294002 and then activated with LPS. As Figure 3b shows,
AKT phosphorylation was suppressed whereas the phosphor-
ylation of p38 and JNK was significantly attenuated. However,
the levels of phospho-ERK remained unchanged regardless
the presence of LY294002. Since PI3K inhibition results in
enhanced IkBa degradation in response to LPS,20,21 the
contribution of this pathway to the phenotype observed in
PTP1B-deficient cells was investigated.19,21–23 Macrophages
challengedwith low doses of LPS exhibited a similar response
in terms of IkBa degradation with negligible recovery at 45min
after PI3K inhibition regardless the presence of PTP1B
(Figure 3c). In the same regard, treatment with recombinant
PTP1B of extracts from PTP1B WT or KO macrophages
activated for 30min with LPS resulted in a robust depho-
sphorylation of all MAPKs but not of AKT (Figure 3d).
Mini-array and microarray analysis of pro-inflammatory
responses in macrophages from PTP1B-deficient mice.
Because PTP1B-deficient macrophages have an enhanced
response to pro-inflammatory stimuli a mini-array analysis of
chemokine and receptors was performed. As Supplementary
Figure S1 summarizes the levels of Ccl2, Ccl5, Ccl7 and
Ccl9, chemokines that recruit inflammatory cells, were
significantly elevated in PTP1B KO macrophages. To better
understand these results, we performed microarray gene
expression analysis in PTP1B WT or KO macrophages. In
all, 276 probes were differentially expressed (DE, false
discovery rate (FDR)o0.05; Figure 4a) in WT versus PTP1B
KO macrophages stimulated with LPS. Among the DE
genes, we identified chemokines (IL-6, CCL2 and CCL17),
which showed significantly higher expression in PTP1B KO
cells, in agreement with qPCR and mini-array results.
Additionally, chemokine (C-X-C motif) ligand 5 (CXCL5) also
showed higher expression in PTP1B-deficient macrophages.
However, an important fraction of DE genes tend to show
lower upregulation after 24 h of LPS challenge in PTP1B KO
cells (Figure 4a, heatmap of only DE genes). Interestingly,
Toll-like receptor 4 (TLR4) was downregulated at 24 h in
PTP1B KO macrophages, suggesting a complex scenario
where deregulation of the inflammatory response in PTP1B-
deficient macrophages is occurring at different levels of the
regulatory network. To get biological insights about the
pathways altered, we performed gene set enrichment
analysis (GSEA) using Kyoto encyclopedia of genes and
genomes (KEGG) and REACTOME pathways (Figure 4b).
Four KEGG pathways were significantly upregulated
(FDRo0.25) in PTP1B KO macrophages (‘p53 signaling’,
‘Base excision repair’, ‘Propanoate metabolism’ and
‘Allograft rejection’) and one REACTOME pathway
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(‘Insulin Synthesis and Processing’). The alterations in
insulin synthesis reflect the known role of PTP1B in insulin
signaling,1–3,5,7,12,24 while the DE in propanoate metabolism
genes suggests a possible novel role for PTP1B in this
pathway. In fact, propionic acid has been associated with
lipogenesis and glucose uptake and has an anti-inflammatory
effect on human macrophages.25,26 The so-called ‘Allograft
rejection’ pathway included PTP1B upregulated inflammatory
genes such as perforin 1, IL-2, CD40LG and IL-12A.
Interestingly, the alteration in p53 and base-excision
Figure 1 Effect of PTP1B deficiency on the polarization of macrophages. Peritoneal macrophages from wild-type (WT) or PTP1B-deficient (KO) mice were isolated after
thioglycollate eliciting. Cells were stimulated with 200 ng/ml of LPS or 25 mg/ml polyI:C (M1 stimuli) and the levels of the indicated proteins were determined at 24 h (a). The
response to M2 stimuli was analyzed after challenge for 24 h with a mixture of 20 ng/ml each IL-4þ IL-13 (b). The levels of PTP1B in M1 and M2 polarized macrophages were
determined (c). The accumulation of NO, PGE2 and TNF-a in the incubation medium was determined after 24 h of activation with 200 ng/ml LPS, 25 mg/ml polyI:C, 5 mg/ml
LTA, 20 ng/ml IL-10 or 20 ng/ml of IL-4þ IL-13 (d). The time course of mRNA levels of IL-6 and NOS-2 after activation with 200 ng/ml LPS (e) and of cells undergoing
apoptosis by annexin V binding criteria (f) were determined. Results show the mean±S.D. of three independent experiments. *Po0.05; **Po0.01 versus the same condition
in the WT cells or non-treated cells (c). (a–c) The band intensities of NOS-2, COX-2 (a), HO-1, Arg-1 (b) and PTP1B (c) after normalization using p85 and b-actin, respectively,
are shown
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pathways could be directly related with the higher sensitivity
of PTP1B-deficient mice to high doses of irradiation.
Notably, PTP1B KO macrophages showed upregulation of
many genes activated after DNA damage (i.e., PCNA,
ATR, CHEK2, GADD45A and BAX) and this exacerbated
response could explain the apoptosis of these cells at 48 h
(Figure 1e).
Effect of silencing human PTP1B on the response of
human monocytes/macrophages to pro-inflammatory
stimulation. PTP1B siRNA efficiently decreased the levels
of PTP1B at the time that moderately increased the
expression of cyclooxygenase-2 (COX-2) after pro-inflammatory
challenge (Figure 5a). In addition to this, the response to
LPSþ IFN-g resulted in a decrease in IkBa (without recovery
as in the murine counterparts) and accelerated IkBb
degradation (Figure 5b). The phosphorylation of AKT and
MAPKs was notably enhanced after silencing PTP1B
(Figure 5b). Also, TNF-a and PGE2 levels measured in the
culture medium increased in cells treated with PTP1B siRNA
(Figure 5c). This enhanced response to pro-inflammatory
challenge in cells with reduced PTP1B levels resulted in a
higher susceptibility to apoptosis in response to LPS and
staurosporine (Figure 5d). Notably, the bright-field morphology
Figure 2 PTP1B deficiency enhances IkBa degradation and impairs IkBa recovery. Macrophages from WT and PTP1B KO mice were stimulated with 200 ng/ml of LPS
for the indicated times and the NF-kB and IRF3 pathways were analyzed (a). The upregulation of IkBamRNA expression as a sensor of resetting of NF-kB was determined by
qPCR (b). The nuclear translocation of p65 was determined by western blotting using p85 and lamin B as markers of the corresponding cytosolic and nuclear fractions,
respectively (c). Results show the mean±S.D. of four independent experiments (b) or a representative blot out of four (a, c). *Po0.05; **Po0.01 versus the same condition
in the WT cells
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of murine and human macrophages lacking PTP1B was
very similar, exhibiting a more fusiform shape than the
corresponding WT cells (Supplementary Figure S2A).
Finally, inhibition of PTP activity with peroxovanadate
(POV) showed a similar profile to that observed after
PTP1B silencing, including the lack in recovery of IkBa, a
higher translocation of p65 to the nucleus (Supplementary
Figure S2B), and a loss in viability, a process that
was partially inhibited by the caspase inhibitor z-VAD
(Supplementary Figure S2C).
Figure 3 PTP1B deficiency enhances AKT and MAPK activation. Macrophages from WT and PTP1B KO mice were stimulated with 200 ng/ml of LPS and the
phosphorylation of AKT, ERK, p38 and JNK was determined at the indicated times (a). To evaluate the effect of the PI3K pathway in the modulation of AKT and MAPK
activities, macrophages from PTP1B KO mice were treated for 10 min before LPS activation with 10 mM LY29004. At the indicated times, the phosphorylation state of these
proteins was determined (b). In parallel to the precedent assays, the levels of IkBa were determined using a lower LPS concentration (50 ng/ml) as stimulus (c). The effect of
recombinant PTP1B on the dephosphorylation of extracts from WT and PTP1B macrophages activated for 30 min with 200 ng/ml of LPS was assayed in vitro after 30 min of
incubation at 30 1C with recombinant PTP1B (d). Results show the mean±S.D. of three independent experiments, or a representative dephosphorylation experiment (d).
*Po0.05; **Po0.01 versus the same condition in the WT cells
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Figure 4 Gene expression profiling of WT and PTP1B-deficient macrophages treated with LPS. Macrophages were activated with 200 ng/ml of LPS for 24 h and the RNA
was extracted, analyzed for quality in a Bioanalyzer and submitted to microarray hybridization (Agilent). Heatmap showing the microarray probes with differential response
(FDRo0.05) to LPS between WT and PTP1B KO macrophages (a). Gene set enrichment analysis (GSEA) of KEGG and REACTOME pathways in macrophages from PTP1B
KO mice after pro-inflammatory stimulation (b). The genes in significantly enriched pathways (FDRo0.25) are shown and the color code corresponds to the standardized
gene expression per row (not LPS fold change as in a). Red indicates higher expression and blue lower expression
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In vivo effects of pro-inflammatory activation in PTP1B-
deficient mice. To determine the in vivo contribution of
PTP1B to pro-inflammatory responses, the basal levels of
TNF-a in serum (Figure 6a), the development of ear edema
(Figures 6b and c), the rise in TNF-a levels in serum
after administration of LPS or zymosan (Figure 6d), the
sensitivity to irradiation (Figure 6e) and the response to
LPS/D-galactosamine (D-GalN) challenge (Figures 6f–i) were
analyzed. The basal levels of TNF-a in serum were
significantly lower in PTP1B KO mice than in the WT
counterparts. However, in the ear pro-inflammatory model
induced after tetradecanoylphorbol acetate (TPA) applica-
tion, PTP1B KO mice exhibited a higher accumulation of
neutrophils, as measured by the myeloperoxidase (MPO)
activity criteria and edema (Figures 6b and c). Also, the
TNF-a levels measured in serum after i.p. challenge with LPS
γ
γ
γ γ
γ
Figure 5 Effect of PTP1B silencing on the response of human macrophages. Human monocytes from buffy coats were differentiated into macrophages and treated with a
mixture of sc- or siRNA oligonucleotides to silence PTP1B. After incubation for 24 h with 200 ng/ml of LPS plus 20 ng/ml of human IFN-g, 25mg/ml of polyI:C or 20 ng/ml of
each human IL-4þ IL-13, the levels of PTP1B and COX2 were determined (a). The time course of the phosphorylation and total levels of proteins related to NF-kB, AKT and
MAPKs were determined (b). The release of TNF-a and PGE2 to the culture medium was determined with specific kits (c). The induction of apoptosis, measured as the
annexin V-positive population, was determined in both resting and LPSþ IFN-g activated cells (d). In addition to this, to determine the sensitivity of cells silenced for PTP1B to
apoptosis in response to pro-inflammatory dependent stimuli the time course and the sensitivity at 36 h to different concentrations of staurosporine (as an stressor to promote
mitochondrial-dependent apoptosis) were determined (d). Results show a representative experiment or the mean±S.D. of three independent experiments. *Po0.05;
**Po0.01 versus the same condition in cells treated with scRNA
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Figure 6 In vivo effect of PTP1B deficiency on the response of mice to different pro-inflammatory challenges. WT or PTP1B KO male mice matched in age were used in
these experiments. The serum levels of TNF-a of untreated animals (n¼ 12) were determined (a). The ear MPO activity and edema (n¼ 10 animals per condition) after topic
administration of TPA was calculated as ratio versus the ear treated with vehicle (b). Fixed ears were stained with eosin/hematoxylin to show the structure and with (sagittal
sections; c). The serum levels of TNF-a of untreated animals or i.p. injected LPS (1 mg/kg body weight) or zymosan (30 mg/kg body weight) were determined at 1 h (n¼ 7
animals per condition) (d). The sensitivity to irradiation after a unique dose of 10 Gy or two doses of 5 Gy administered in an interval of 4 h (n¼ 15 per group) was evaluated as
survival after 7 days post transplantation (Tx) of the corresponding bone marrow; P¼ 0.0005 versus the WT at 10 Gy (e). The liver injury, determined by the measurement of
the ALT activity in the serum (f) and structure (eosin/hematoxylin staining at 4 h; white bar¼ 100mm; g), and the survival of animals after i.p. administration of a single dose of
LPS/D-GalN (n¼ 12 animals per condition) were determined; P¼ 0.074 versus the WT (h, left). Alternatively, a series of WT animals underwent irradiation (10 Gy) as depicted
in (e), and were subsequently submitted to bone marrow transplantation from WT or PTP1B KO mice. After restitution of the immune system (12 weeks), these animals
were submitted to LPS/D-GalN challenge and survival was determined (h, right). The TNF-a levels after 1 h of treatment with LPS/D-GalN were determined in serum from
animals of (i). Results show the mean±S.D. of the indicated number of animals and/or the Kaplan–Meier representation of survival (e and h). *Po0.05; **Po0.01 versus the
same condition in the WT animals or samples
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or zymosan were significantly higher in the PTP1B KO
counterparts. Interestingly, these animals were very sensi-
tive to irradiation and at least 90% died in o2 days when
treated with 10Gy, linking this response to the activation of
the p53 and excision base repair pathways observed in the
microarray (Figure 4b). Opposite to this situation 70% of
the WT mice were alive. When the same quantity of
irradiation was administered in two doses in a 4-h interval,
490% of the animals survived regardless the absence
of PTP1B.
PTP1B KO mice challenged with LPS/D-GalN exhibited a
higher liver injury than the WT counterparts as assessed by
the rapid rise in serum alanine aminotransferase (ALT) activity
(Figure 6f) and the loss of liver integrity (Figure 6g). These
PTP1B KO mice exhibited a higher rate of death upon
LPS/D-GalN administration (Figure 6h, left), that was
abrogated when the experiments were repeated in irradiated
WT animals reconstituted with bone marrow from PTP1B KO
donor mice (Figure 6h, right), suggesting that resident liver
macrophages (Kupffer cells?), or even hepatocytes, have a
key role in the liver-induced animal death. Interestingly, the
TNF-a levels in the serum of these animals at 1 h reflected a
minimal, but statistically significant increase when the
circulating monocytes were from PTP1B KO mice
(Figure 6i). In addition to this approach, mice were treated
with clodronate to remove resident macrophages. Under
these conditions, reconstitution ofWT-irradiated mice with the
bone marrow from PTP1B KO animals failed to show
differences in survival after LPS/D-GalN challenge; however,
the levels of TNF-a in serum after LPS/D-GalN were
significantly lower than those obtained in the above reported
experimental models (avoiding clodronate treatment), which
might explain the absence of differences in survival between
both groups (Supplementary Figure S3A and B). Regarding
the quality of the macrophage replenishment, RT-PCR
analysis ensured that the liver population after transplantation
was from the PTP1B KO donors (Supplementary Figure S3C)
and, in the absence of transplantation, all F4/80-positive liver
population was removed after 48 h of clodronate treatment
(Supplementary Figure S3D).
Discussion
Macrophages respond very efficiently and regulate several
signaling pathways in a strict temporal pattern in which
resolution is a key component.27,28 Among the systems that
modulate this response, protein phosphatases exert a
significant role.29 Several reports suggested that PTP1B is
an important modulator of the activation process of macro-
phages restricting the time of pro-inflammatory signaling in
response to TLR and to both type I and type II IFN
signaling.14,18,30–32 Also, PTP1B could be increased or
activated by inflammatory factors such as TNF-a.33 Intrigu-
ingly, these observations contrast with results obtained in
myeloid-cell (LysM)-PTP1B KO mice, despite to show
enhanced NOS-2 expression and accumulation of nitrite in
the medium upon LPS challenge,34 and in a murine model of
experimental colitis.35 Opposite to these results, other studies
have identified an essential role for PTP1B in obesity-induced
inflammation, in regulating leukocyte recruitment during
allergic inflammation and in macrophage development.30,32,36
At the same time, evidence from the area of diabetes has
suggested that inhibition of PTP1B might be envisaged as a
way to prolong insulin action.3,5,12,36 Keeping in mind these
ideas, we have investigated whether the deficiency of PTP1B
in murine and human macrophages affects the regulation of
the response of these cells to pro-inflammatory and
anti-inflammatory stimuli. Our data show that peritoneal
macrophages from PTP1B KO mice presented an exacer-
bated inflammatory response versus the WT, with increased
production of M1 polarization markers. Moreover, this
enhanced activation in PTP1B KO macrophages was not
restricted to TLR4 signaling but also occurred in response to
TLR2 (lipoteichoic acid, LTA) and TLR3 (polyI:C) challenge,
confirming preliminary data in the Raw 264.7 macrophage cell
line.18 Conversely, in the absence of PTP1B, macrophages
show an impaired response to IL-4 plus IL-13 resulting in
attenuated M2 polarization that suggests a dual role for
PTP1B in the regulation of M1/M2 commitment. It is well
known that induction of target genes upon TLR stimulation
requires a combination of downstream signaling events,
including transcriptional activation via NF-kB factors and
activation of the PI3K/AKT and MAPK pathways.37–39 The
enhanced signaling of these three pathways in PTP1B-
deficient macrophages suggests that PTP1B acts as a
common negative regulator of NF-kB, AKT and MAPK
activities. In this regard, the more efficient degradation of
IkBa together with its delayed resynthesis in PTP1B KO
macrophages resulted in a persistent and augmented p65
translocation to the nucleus and, therefore, of NF-kB DNA
binding activity consistently with the observed exacerbated
inflammatory responses.
Several studies have shown that the PI3K/AKT pathway
exerts a key role in the regulation of the innate immune
responses under pro-inflammatory conditions and against
different pathogens.20–23,39 In agreement with previous
reports performed in hepatocytes,7,36 in this study we have
shown that PTP1B deficiency induces an increased and
persistent AKT phosphorylation in human and mouse macro-
phages. This AKT activation was dependent on PI3K activity
as far as it was suppressed by the broad PI3K inhibitor
LY294002. Moreover, in the presence of this inhibitor the
levels of phospho-p38 and phospho-JNK were significantly
reduced whereas the phosphorylation of ERK remained
unaffected, indicating a complex regulatory network at early
steps of the pro-inflammatory signaling, and orchestrated by
the PI3K/AKT pathway. In this regard, the inhibition of
PI3K/AKT resulted in an almost indistinguishable overactiva-
tion of the NF-kB pathway with a delayed resetting of IkB
levels, regardless the presence or absence of PTP1B (see
Figure 3c). PTP1B dephosphorylates downstream substrates
through its phosphatase activity and we found that PTPT1B
deficiency significantly increased the phosphorylation of
MAPKs and AKT; however, the treatment of extracts from
WT or PTP1B KO macrophages with recombinant PTP1B
lead to a significant dephosphorylation of all MAPKs but not
of AKT. These findings suggest that MAPKs are direct
substrates of PTP1B and, therefore, PTP1B negatively
regulates LPS responses in macrophages through its
phosphatase activity.
PTP1B modulation of macrophage responses
PG Trave´s et al
9
Cell Death and Disease
Another relevant aspect in PTP1B biology is its involvement
in the endocytosis of IFN-a/b receptor chain 1 in human but
not in murine cells31 and therefore, restricting antiviral
therapies. However, in terms of regulation of inflammatory
responses both human and murine macrophages behave
similarly. Indeed, we observed that silencing PTP1B in human
macrophages significantly reduced cell viability, counter-
acting in this way the potential beneficial aspects of the use
of PTP1B inhibitors.40–42 Moreover, this loss of viability due to
reduced PTP1B activity, even under basal conditions, was
also reproduced by broad and transient PTP inhibitors, such
as POV, indicating that the activity of these PTPs is required at
specific moments of cell activation to maintain cell viability.
Therefore, caution should be taken in the development of
strategies of inhibition of PTP1B activity, at least under
circumstances in which maintenance of cell viability is a
requisite (i.e., phagocytosis). In addition to this, the mini-array
data obtained after short periods of pro-inflammatory activa-
tion confirmed the enhanced pro-inflammatory responses
expected from targets downregulated by this PTP. However,
when we performed a microarray analysis at 24 h after LPS
challenge we realized that the main differences in gene
expression were not related to pro-inflammatory genes, but to
very specific pathways: the p53 and DNA excision/repair
pathways and the propanoate metabolism pathway. Interest-
ingly, the link between the p53 pathway and the DNA excision/
repair pathway fits with the observed loss of viability of
PTP1B-deficient cells. Moreover, when we irradiated the
animals to perform bone marrow transplantation, we were
surprised by the extreme sensitivity of the PTP1B KO mice,
compatible with an enhanced DNA injury. This role of PTP1B
in protecting mice against irradiation injury is a relevant issue
of the present work and we reasoned that perhaps strategies
to improve transient PTP1B activity in the course of irradiation
will have beneficial effects. Moreover, the levels of PTP1B are
consistently increased after pro-inflammatory challenge in
macrophages, perhaps as a way to improve cell viability under
conditions of intense synthesis of reactive oxygen and/or
nitrogen species that may damage the DNA.
Regarding the in vivo experiments in PTP1B-deficient
animals, according to our results and those from other
groups,30 we observed an enhanced ear edema in these
animals, compatible with an increased leukocyte trafficking,
as deduced by the higher levels of MPO in the ear samples. In
addition to this, we evaluated the effects of PTP1B deficiency
in the LPS/D-GalN model that evidences TNF-a toxicity in the
liver. In this way, under identical conditions, animal death
(mainly by liver hemorrhage) was significantlymore prominent
in the PTP1B KO mice, together with minimally, but
statistically significant higher serum levels of TNF-a in PTP1B
KO mice. However, when we performed bone marrow
transplantation and reintroduced the PTP1B KO myeloid
system into the WT animals, the rates of survival were
identical between both groups, suggesting that perhaps the
main contribution to the animal death upon LPS/D-GalN
challengewas not the circulatingmonocyte/macrophages, but
the tissue resident population of the liver. Using clodronate
administration as a strategy to deplete tissue macrophages
and to replenish the organs with themyeloid cells coming from
the transplanted bone marrow,43 we analyzed the effect of
reintroduction of myeloid cells from PTP1B KO mice into
irradiated WT counterparts and then performed the LPS/D-
GalN challenge; however, again it was impossible to
distinguish between the two groups. One possible explanation
is that the levels of TNF-a reached in both models were very
similar and lower than those measured in the absence of
clodronate depletion. Alternatively, the fact that our PTP1B
KO mice lack of this enzyme in all tissues, including the liver,
cannot exclude a contribution of the hepatocytes as a result of
a paracrine effect to the increased sensitivity to LPS/D-GalN
observed in the intact PTP1B KO model. Finally and in an
intriguing way, it has been reported that PTP1B deficiency
confers resistance against apoptosis induced by pro- and anti-
inflammatory stimuli such as transforming growth factor b
(TGF-b), TNF-a or resveratrol in hepatocytes and brown
adipocytes.8 Our observation that even under basal condi-
tions the viability of human and murine macrophages is
reduced in the absence of PTP1B suggests the existence of
alternative pathways linking cell viability to its presence in
immune cells. In fact, a cross-talk between different groups of
PTP members has been described as a regulatory network to
ensure sufficient immunity against pathogen challenge and in
preventing adverse autoimmune responses.29 In conclusion,
our data show a previously unrecognized genetic damage in
myeloid cell upon pro-inflammatory activation, and suggest
that the broad use of PTP1B inhibitors, although with potential
benefits over the insulin signaling pathway, might exert
undesirable effects in response to stressors of the immune
system including the fine tuning of the pro-inflammatory and
pro-resolution balance.
Materials and Methods
Materials. Common reagents including z-VAD.FMK were from Sigma-Aldrich
(St Louis, MO, USA) or Roche (Darmstadt, Germany). Murine or human cytokines
were obtained from PeproTech (London, UK). Antibodies were from Ambion
(Austin, TX, USA), Santa Cruz Biotech (Santa Cruz, CA, USA) or Cell Signaling
(Danvers, MA, USA). Reagents for electrophoresis were from Bio-Rad (Hercules,
CA, USA) and Sigma-Aldrich. Tissue culture dishes were from Falcon (Lincoln
Park, NJ, USA), and serum and culture media were from Invitrogen and Gibco
(Life Technologies/Thermo Fisher, Madrid, Spain).
Animal care and preparation of macrophages. Male and female
PTP1B heterozygous (HET) mice, maintained on a mixed genetic background
(C57BL/6 129sv), were intercrossed to yield the three genotypes of mice (WT,
HET and KO). In this study, we used 8- to 12-week-old WT and PTP1B KO male
mice housed under 12 h light/dark cycle and food and water was provided ad
libitum. Animals were cared for according to a protocol approved by the Ethical
Committee of our institution (following directive 2010/63/EU of the European
Parliament). PTP1B-deficient mice were used as previously described.36 Elicited
peritoneal macrophages were obtained from male mice 4 days after intraperitoneal
(i.p.) administration of 2.5 ml of 3% thioglycollate broth essentially as described
previously.44 Cells were seeded in 6-multiwell plates at a density of 4 106 cells/
plate and cultured in RPMI-1640 medium supplemented with 10% heat-inactivated
fetal calf serum (FCS) and antibiotics (100 U/ml penicillin, 100mg/ml streptomycin)
at 37 1C in a humidified atmosphere with 5% CO2. After 2 h of incubation, non-
adherent cells were removed. Adherent cells were maintained in these culture
conditions and used within 2 days after plating. After overnight serum reduction,
cells were challenged with LPS, polyI:C and LTA (as M1 stimuli) or with IL-4, IL-13
and IL-10 (as M2 stimuli).
Isolation of human monocytes. PBMCs were isolated from enriched
buffy coats of healthy donors by separation on Ficoll-Hypaque Plus (GE
Healthcare, Madrid, Spain) following the manufacturers’ protocol. After washing
the upper layer, CD14þ cells were obtained using immunomagnetic isolation
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(Miltenyi Biotec, Bergisch, Germany). Cells were maintained for 4 h at 1 106
cells/ml in DMEM supplemented with antibiotics (100 IU/ml penicillin and
100mg/ml streptomycin). After this period, the supernatant was removed and
adherent cells were cultured in the same medium supplemented with 10%
heat-inactivated FCS. Cells were maintained overnight with this medium and
differentiated into macrophages with hM-CSF (20 ng/ml; PeproTech) for 7 days.
Silencing of PTP1B in human monocyte/macrophages. Human
differentiated macrophages were incubated with Opti-Mem (Gibco)
supplemented with 10% FCS and after 4 h in this medium were treated with
50 nM scrambled (sc)- or siRNAs specific for human PTP1B (Dharmacon,
Madrid, Spain). Transfection was accomplished with lipofectamine RNAiMAX
(Invitrogen) following the instructions of the supplier. After 12 h, the dishes
were supplemented with 2 vol of complete medium containing 10% FCS and
antibiotics and maintained for an additional 24-h period. Cell viability was
ensured after this incubation and the plates were washed twice with PBS and
incubated with fresh medium containing 2% FCS. Cells were used 12 h after
this step.
Preparation and treatment of murine or human macrophages
with POV. A fresh solution of POV was used to mimic broad PTP inhibition.
Briefly, POV was prepared by incubating 1 mM vanadate in PBS with 1 mM H2O2
for 10 min at 30 1C.45 The mixture was treated with purified recombinant catalase
(200mg/ml) to remove the residual H2O2 and was used in the next 10 min by
adding the solution to the culture medium. As a control, cells received a solution
prepared in parallel, but lacking vanadate (this preparation was referred to as
vehicle in the same set of experiments).
Determination of ALT activity and NO, TNF-a and PGE2 levels.
The ALT activity was determined in serum samples using a Reflotron plus device
(Roche). The amount of nitrate and nitrite in the culture medium was measured
after reduction of nitrate to nitrite, and quantification of nitrite using a previous
protocol.44 The accumulation of TNF-a or PGE2 in the culture medium was
measured using specific immunoassay kits (GE Healthcare). The levels of TNF-a
in serum were measured under similar conditions following the instructions of the
immunoassay kit supplier.
Measurement of cell viability. Macrophage viability was determined by
flow cytometry as follows: cells were seeded in TPP dishes that favor its
detachment with cold PBS. After centrifugation at 4 1C for 5 min at 1000 g, cells
were resuspended in 10 mM HEPES; pH 7.4, 140 mM NaCl, 2.5 mM CaCl2 and
labeled with annexin V–FITC (Invitrogen) solution and/or propidium iodide (PI)
(10mg/ml) for 15 min at RT in the dark and then analyzed in a BD-Canto flow
cytometer (BD Biosciences, Madrid, Spain). PI is impermeable to living but stains
necrotic and apoptotic dying cells with impaired membrane integrity in contrast to
annexin V, which stains early apoptotic cells.
Preparation of total protein cell extracts. Macrophages were
homogenized in a buffer containing 10 mM Tris-HCl, pH 7.5; 1 mM MgCl2,
1 mM EGTA, 10% glycerol, 0.5% CHAPS, 1 mM b-mercaptoethanol and 0.1 mM
PMSF and a protease and phosphatase inhibitor cocktail (Sigma-Aldrich). The
extracts were vortexed for 30 min at 4 1C and after centrifuging for 20 min at
13 000 g, the supernatants were stored at  20 1C. Protein levels were
determined using Bradford reagent (Bio-Rad).
Western blotting. Protein extracts were boiled in loading buffer (250 mM
Tris-HCl; pH 6.8, 2% sodium dodecyl sulfate (SDS), 10% glycerol and 2%
b-mercaptoethanol) and 30mg of protein were subjected to 8–10% SDS
polyacrylamide gel electrophoresis (SDS-PAGE) electrophoresis gels. Proteins
were transferred onto polyvinylidene fluoride (PVDF) membranes (GE Healthcare).
Membranes were incubated for 1 h with low-fat milk powder (5%) in PBS
containing 0.1% Tween-20. Blots were incubated for 2 h or overnight at 4 1C with
primary antibodies against NOS-2, COX-2, KC, MIP2, IP10, SOCS3, PTP1B, HO-
1, Arg-1, IRF-3, p65, and the specific anti-phospho- or total AKT, ERK, p38 and
JNK at the dilutions recommended by the suppliers. The blots were developed
with ECL Advance protocol (GE Healthcare) and different exposure times were
performed for each blot with a Charged Coupling Device camera in a luminescent
image analyzer (Molecular Imager; Bio-Rad) to ensure the linearity of the band
intensities. Blots were normalized for lane charge using antibodies against
p85-PI3K, GAPDH or b-actin. Values of densitometry were determined using the
Quantity One software (Bio-Rad).
RNA isolation and RT-PCR analysis. RNA was extracted with TRIzol
Reagent (Invitrogen) and reverse transcribed using Transcriptor First Strand cDNA
Synthesis Kit for RT-PCR following the indications of the manufacturer (Roche).
Real-time PCR was conducted with SYBR Green Master (Roche) on a MyiQ
Real-Time PCR System (Bio-Rad). Primer sequences for mouse IL-6, NOS-2,
IkBa and PTP1B are available on request. Validation of amplification efficiency
was performed for each pair of primers.44 PCR thermocycling parameters were
95 1C for 10 min, 40 cycles of 95 1C for 15 s, and 60 1C for 1 min. Each sample
was run in duplicate and was normalized versus 36B4. The fold induction (FI) was
determined in a DDCt-based fold-change calculation.
Mini-array and microarray analysis. Differential expression at 0 and 3 h
was tested using the ‘Chemokine and Receptors’ 96-well PCR mini-array (Qiagen,
Madrid, Spain; ref. PAMM-022Z) and RNA samples of peritoneal macrophages
from WT and PTP1B KO mice challenged with LPS. RNA extraction and
expression analysis was performed according to the instructions of the supplier
(Qiagen). In addition to this, normalized expression data in macrophages after 24 h
of stimulation were obtained in our core facility, using a mouse microarray platform
(Agilent-014868 Whole Mouse Genome Microarray 4 44K G4122F). Quality of
the samples was ensured in a Bioanalyzer 2100. Processing, normalization and
differential expression were performed using Limma Bioconductor package.46
Enrichment of gene sets of interest from KEGG and REACTOME was
accomplished using the GSEA software as described by Mootha et al.47
Bone marrow transplantation and clodronate treatment. Eight- to
nine-week-old C57BL/6 129sv WT male mice were irradiated with a dose of
1000 rads (10 Gy) by a cesium g-source. One-week prior and 2-week post bone
marrow transplantation, 100 mg/l neomycin and 10 mg/l polymyxin B sulfate
(Sigma-Aldrich) were added to the acidified water. The bone marrow was collected
from the femurs and tibias of 8- to 9-week-old donor male PTP1B WT or KO mice
(C57BL/6 129sv) by flushing femurs with phosphate-buffered saline. Each
recipient mouse was injected with about 5–6 106 bone marrow cells by
retroorbital injection 4 h after irradiation. In another set of animals, 2 weeks after
irradiation, mice were injected 200ml of clodronate- or PBS-loaded liposomes
(www.clodronateliposomes.com) by retroorbital injection.43 Twelve weeks after
transplantation, genomic DNA was harvested from whole blood and liver for use in
PCR-based genotyping of WT and PTP1B-deficient alleles.36 In addition to this,
liver sections were prepared and stained with F4/80-FITC and laminin to ensure
the depletion of Kupffer and resident macrophages.
In vivo evaluation of sensitivity to LPS/D-GalN treatment. To
evaluate the in vivo response to inflammatory challenge, PTP1B WT and KO
animals were injected (i.p.) a low dose of LPS (2 mg/kg) in combination with
D-GalN (800 mg/kg) and animal survival was evaluated. In addition to this, WT
mice transplanted with bone marrow from PTP1B KO or WT donors with or without
treatment with clodronate liposomes to decrease resident macrophage populations
were also used for applying the LPS/D-GalN protocol. Serum from these animals
was prepared from blood obtained by retroorbital puncture. Liver sections were
prepared and stained with eosin/hematoxylin to determine the macroscopic
integrity of the tissue upon LPS/D-GalN administration.
Measurement of ear edema and MPO activity. TPA (2.5mg) dissolved
in 20ml acetone was applied in 10ml volumes to both the inner and the outer
surfaces of the left ear of mice (20–25 g), and the same procedure was repeated
in the right ear with the vehicle. Animals were killed after 4 h, and equal-sized
samples of both ears were punched out and weighed. Edema was measured as
the weight difference between the right and left ear samples. These ear samples
were homogenized in 500ml of ice-old PBS, snap frozen and thawed four times,
subsequently submitted to sonication (twice for 10 s) and centrifuged at 10 000 g
for 15 min at 4 1C. MPO activity was measured in the supernatants as a marker for
neutrophil infiltration. Aliquots of supernatants (50 ml) were assayed in a reaction
mixture that contained 110ml PBS, 20ml of 0.22 M NaH2PO4 (pH 5.4), 20ml of
0.026% (v/v) H2O2, and 20ml of 18 mM tetramethylbenzidine in 8% (v/v) aqueous
dimethylformamide. After 10 min of reaction at 37 1C, 30ml sodium acetate (1.5 M;
pH 3) was added, and the absorbance at 620 nm was read in a microtiter plate
reader. The activity was expressed as mU/mg protein.48,49 In addition to this, ears
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were fixed with paraformaldehyde and stained with eosin/hematoxylin to visualize
their structure and extension of the edema.
Analysis of PTP1B-mediated dephosphorylation. Macrophages
from PTP1B KO mice were stimulated with LPS (200 ng/ml) for 30 min and
immediately homogenized in buffer containing 20 mM imidazole-HCl, 2 mM EGTA
and 2 mM EDTA (pH 7.0) supplemented with protease inhibitors (10 mg/ml
leupeptin, 10 mg/ml aprotinin and 1 mM PMSF). Samples were sonicated 3 15 s
at 1.5 mA and lysates were clarified by centrifugation at 12 000 g for 10 min.
After protein content determination, 60 ml of cell lysates (1 mg/ml) was incubated
with 10 units of recombinant PTP1B (Upstate, Merck-Millipore, Darmstadt,
Germany) for 30 min at 37 1C. The reaction was stopped by adding Laemmli’s
buffer and samples were analyzed by western blotting.
Statistical analysis. The values in graphs correspond to the means±S.D.
The statistical significance was determined with Student’s t test for unpaired
observation. Data were analyzed by the SPSS for Windows statistical
package, v21 (IBM, Madrid, Spain).
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